 Sirolimus
"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 4 | 1 | 5 | | 2000 | 6 | 1 | 7 | | 2001 | 4 | 2 | 6 | | 2002 | 1 | 0 | 1 | | 2003 | 5 | 2 | 7 | | 2004 | 2 | 4 | 6 | | 2005 | 3 | 3 | 6 | | 2006 | 4 | 2 | 6 | | 2007 | 6 | 2 | 8 | | 2008 | 6 | 4 | 10 | | 2009 | 6 | 3 | 9 | | 2010 | 13 | 4 | 17 | | 2011 | 7 | 6 | 13 | | 2012 | 6 | 2 | 8 | | 2013 | 10 | 7 | 17 | | 2014 | 7 | 8 | 15 | | 2015 | 2 | 2 | 4 | | 2016 | 8 | 4 | 12 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 2 | 3 | | 2019 | 4 | 1 | 5 | | 2020 | 1 | 3 | 4 | | 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Wahl D, Cavalier AN, Smith M, Seals DR, LaRocca TJ. Healthy Aging Interventions Reduce Repetitive Element Transcripts. J Gerontol A Biol Sci Med Sci. 2021 04 30; 76(5):805-810.
-
Hardesty A, Pandita A, Vieira K, Rogers R, Merhi B, Osband AJ, Aridi J, Shi Y, Bayliss G, Cosgrove C, Gohh R, Morrissey P, Beckwith CG, Farmakiotis D. Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. Transplant Proc. 2021 May; 53(4):1187-1193.
-
Pohl K, Grimm XA, Caceres SM, Poch KR, Rysavy N, Saavedra M, Nick JA, Malcolm KC. Mycobacterium abscessus Clearance by Neutrophils Is Independent of Autophagy. Infect Immun. 2020 07 21; 88(8).
-
Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR As an Essential Kinase in SCLC. J Thorac Oncol. 2020 09; 15(9):1522-1534.
-
Abu Shehab M, Biggar K, Kakadia JH, Dhruv M, Jain B, Nandi P, Nygard K, Jansson T, Gupta MB. Inhibition of decidual IGF-1 signaling in response to hypoxia and leucine deprivation is mediated by mTOR and AAR pathways and increased IGFBP-1 phosphorylation. Mol Cell Endocrinol. 2020 07 15; 512:110865.
-
Ornelas IM, Khandker L, Wahl SE, Hashimoto H, Macklin WB, Wood TL. The mechanistic target of rapamycin pathway downregulates bone morphogenetic protein signaling to promote oligodendrocyte differentiation. Glia. 2020 06; 68(6):1274-1290.
-
Shokati T, Hartmann M, Davari B, Klawitter J, Klawitter J, Christians U. Temsirolimus metabolic pathways revisited. Xenobiotica. 2020 Jun; 50(6):640-653.
-
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019 Aug; 6(8):e409-e418.
-
Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196.
-
Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J. 2019 04; 53(4).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|